Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.Search publications
Alerts and app
Email alerts

Data sources

Source-labeled psilocybin and psilocin literature for search, monitoring, export, and citation workflows.

How the research index is built

Eight research sources feed Psilocybin-Research.com PubMed, OpenAlex, Crossref, Europe PMC, ClinicalTrials.gov, PsyArXiv, bioRxiv, and medRxiv provide records that are reconciled into the central research index. psilocybin-research.com PubMed OpenAlex Crossref Europe PMC ClinicalTrials.gov PsyArXiv bioRxiv medRxiv
Source records are fetched, reconciled, and labeled before appearing in the live index. The original sources remain authoritative.

Research workflow

Search, filter, export, analyze, and monitor publications with source labels, publication status, citation links, alerts, API access, and a rights-safe SQLite download. Read about the methods and limitations. Explore the dataset and reuse guide or research trends by year.

Published

Improving access to novel treatments for treatment-resistant depression: The potential role of specialist clinics in Australia.

An abstract is available from the original source but is not redistributed by this database. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal
The Australian and New Zealand journal of psychiatry
Date
2026-07-01
Source
PubMed
DOI
10.1177/00048674261450390
PubMed
42198984

Authors

Giri YFurst PLoo CKClark SRTibrewal P
Watch author

Derived topics and classifications

psilocybin DepressionTreatment-Resistant Depression Other

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Improving access to novel treatments for treatment-resistant depression: The potential role of specialist clinics in Australia.2026-07-01

Related papers

Beyond Monoamines: Ketamine, Esketamine, and Classic Psychedelics in the Treatment of DepressionZenodo (CERN European Organization for Nuclear Research) · 2026-07-17Psychedelics and ketamine/esketamine in depressive disorders: biological mechanisms and associated neuroimaging and clinical changes.Translational psychiatry · 2025-10-31Lessons learned from the regulatory alignment in ketamine, esketamine and arketamine clinical trials: A cross-sectional analysis of protocols from ClinicalTrials.gov.Psychiatry research · 2025-08-01Control Group Outcomes in Trials of Psilocybin, SSRIs, or Esketamine for Depression: A Meta-Analysis.JAMA network open · 2025-07-01Announcement of special issue: ‘Behavioural pharmacology of ketamine and psychedelic drugs’Behavioural Pharmacology · 2026-05-06AI-assisted characterization of psychedelic clinical trials from ClinicalTrials.govTrials · 2026-10-14Psychedelics, entactogens and psychoplastogens for depression and related disorders.British journal of pharmacology · 2026-07-01Psychedelics in treatment-resistant depression: a comprehensive review of mechanisms, clinical evidence, and recommendations.Neuropsychiatrie: Klinik, Diagnostik, Therapie und Rehabilitation: Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater · 2026-06-30